anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In order to determine the behavior of the right ventricle, we have reviewed the existing literature in the area of cardiac remodeling, signal transduction pathways, subcellular mechanisms, β-adrenoreceptor-adenylyl cyclase system and myocardial catecholamine content during the development of left ventricular failure due to myocardial infarction. The right ventricle exhibited adaptive cardiac hypertrophy due to increases in different signal transduction pathways involving the activation of protein kinase C, phospholipase C and protein kinase A systems by elevated levels of vasoactive hormones such as catecholamines and angiotensin II in the circulation at early and moderate stages of heart failure. An increase in the sarcoplasmic reticulum Ca2+ transport without any changes in myofibrillar Ca2+-stimulated ATPase was observed in the right ventricle at early and moderate stages of heart failure. On the other hand, the right ventricle showed maladaptive cardiac hypertrophy at the severe stages of heart failure due to myocardial infarction. The upregulation and downregulation of β-adrenoreceptor-mediated signal transduction pathways were observed in the right ventricle at moderate and late stages of heart failure, respectively. The catalytic activity of adenylate cyclase, as well as the regulation of this enzyme by Gs proteins, were seen to be augmented in the hypertrophied right ventricle at early, moderate and severe stages of heart failure. Furthermore, catecholamine stores and catecholamine uptake in the right ventricle were also affected as a consequence of changes in the sympathetic nervous system at different stages of heart failure. It is suggested that the hypertrophied right ventricle may serve as a compensatory mechanism to the left ventricle during the development of early and moderate stages of heart failure.
Cohort 2 comprised subjects with "refractory" disease, defined as subjects who either (a) were treated with 1 previous line of chemotherapy and either had no response or progressed \< 90 days after completing treatment or (b) required third-line therapy, i.e., had completed 2 previous lines of chemotherapy, regardless of response. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m\^2) followed by 1 week of follow-up in each treatment cycle.
This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
CNS stimulants, including Methylphenidate hydrochloride extended-release tablets, have a high potential for abuse. Abuse is characterized by impaired control over drug use despite harm, and craving.

Signs and symptoms of CNS stimulant abuse include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed. Abusers of CNS stimulants may chew, snort, inject, or use other unapproved routes of administration which may result in overdose and death [see Overdosage (10)]. 

To reduce the abuse of CNS stimulants including Methylphenidate hydrochloride extended-release tablets, assess the risk of abuse prior to prescribing. After prescribing, keep careful prescription records, educate patients and their families about abuse and on proper storage and disposal of CNS stimulants [see How Supplied/Storage and Handling (16)], monitor for signs of abuse while on therapy, and reevaluate the need for Methylphenidate hydrochloride extended-release tablets use.
50 individuals with Chronic Neck Pain not working will be included to our study. We will evaluate pain (with visual analog scale), deep neck flexors' endurance (with cranio-cervical flexure test using the pressure stabilizing feedback device), cervical range of motion and cervical proprioception (wit cervical range of motion device). Besides we will conduct a questionnaire (neck disability index) to get further knowledge about their functionality. Participants will be randomly allocated 2 groups consisting of 25 participants and these 2 groups will receive different interventions. Modified Pilates Exercise Group (MPEG) will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week in the presence of a physiotherapist. The Control Group (KG) will receive daily routine advises to prevent neck pain and they will be asked about to apply these advises and not to make other changes in their life. The evaluations will be repeated and analyzed 2 times, pre-treatment and 6 weeks after treatment , and the effectiveness of the modified pilates exercises will be examined in the chronic neck pain. Our hypothesis is ''Modified pilates exercises have a positive effect on neck pain, range of motion, deep neck flexor muscles, joint position sense and function in patients with chronic neck pain.''
PURPOSE: An antimicrobial peptide derived from abalone is provided to show an antimicrobial activity against fish pathogenic microorganisms without harm to human body and fish because the peptide does not have a hemolytic activity in erythrocytes of human and fish. CONSTITUTION: A peptide with an amino acid of sequence number 1 has an antimicrobial activity. The peptide is derived from Haliotis discus. The peptide has an antimicrobial activity against gram positive bacteria and gram negative bacteria. The peptide does not damage erythrocytes of human and fish. A gene encodes the peptide. Antibiotics contain the peptide as an active ingredient. [Reference numerals] (AA) Abalone Gill extract
Despite the fact that influenza vaccination of pregnant women is amply recommended, coverage of influenza vaccination is low. In general, there are few studies on safety of the vaccine to this group, particularly during the first three months of pregnancy or evaluating trivalent vaccines containing inactivated pandemic 2009 H1N1 virus. Studies are controversial regarding passage of maternal antibodies and protection to the newborn. The investigators propose to evaluate safety and immunogenicity of 2011-2012 seasonal trivalent influenza vaccine (Northern hemisphere)(containing an A/California/7/2009 (H1N1)-like virus; an A/Perth/16/2009 (H3N2)-like virus; a B/Brisbane/60/2008-like virus) produced by Sanofi Pasteur. Study design is a Phase II/III, two arm, non-randomized clinical trial. The investigators will recruit 120 pregnant women, 18 to 39 years of age, 14 to 34 week pregnant and 120 non-pregnant women. Trivalent influenza vaccine (0.5ml) will be administered IM in the deltoid zone. Participants will be observed for 30 min post-vaccination for acute adverse reactions and periodically during the 60 days post-vaccination for reactogenicity, adverse effects and severe adverse effects. Baseline and 28 day influenza antibodies will be measured by hemagglutination and microneutralization. Umbilical cord blood (10ml) will be drawn during delivery. Newborns will be followed monthly for growth and morbidity up to six months of age. If necessary, they will be referred for appropriate clinical care. Main outcome will be seroconversion and seroresponse at 28 days post vaccination. Results will be adjusted by study group and other relevant covariables.Safety will be analyzed according to type, severity and study group.
Despite bypass surgery has been considered as the standard strategy for the treatment of unprotected left main coronary artery (LMCA) lesions, several studies have demonstrated that percutaneous coronary intervention (PCI) of the unprotected LMCA is feasible and appears to be an alternative strategy in selected patients. However, the safety and efficacy of PCI in patients with unprotected LMCA stenosis are still a matter of debate.

Previous studies have demonstrated the safety and feasibility of unprotected LMCA intervention using bare metal stents (BMS). There was a favorable initial outcome after LMCA intervention using BMS in low-risk patients. However, in-stent restenosis after BMS implantation has emerged as the interference to widely perform PCI for unprotected LMCA lesions and the most important reason for selection of bypass surgery as the first choice for treating LMCA stenosis. In-stent restenosis in these patients not only influences long-term survival, but also make repeat intervention more complex. Despite endeavors to decrease in-stent restenosis after LMCA intervention using BMS, such as aggressive debulking atherectomy, the restenosis rate still remains at 20-30%. The sirolimus-eluting stent (SES) (Cypher, Cordis, Johnson \& Johnson Corp, Miami, Florida) markedly decreases in-stent restenosis in elective patients with relatively simple coronary lesions. In real-world practice using SES, patients undergoing SES implantation were treated with a less restrictive interventional approach. However, the results are very promising similar to the randomized controlled trials. These findings warrant new studies to compare the efficacy of SES for more complex lesion subsets including LMCA disease with coronary artery bypass graft (CABG).
The invention discloses a medicament for treating qi-blood deficiency. The medicament is prepared from the following raw materials in part by weight: astragalus, ginseng, dangshen, large-head atractylodes rhizome, poria, sealwort, liquoric root, Chinese angelica, rice malt and epimedium herb. Qi-blood deficiency is caused by hematozemia and damage to vigor due to aeipathia, post-natal insufficient source of vital function and source-free qi-blood metaplasia, and causes deficient yang energy of spleen and kidney. Qi-blood deficiency is treated by replenishing qi and blood, strengthening the spleen and tonifying the kidney. The astragalus, the ginseng, the dangshen, the large-head atractylodes rhizome, the poria, the sealwort and the liquoric root have the effects of strengthening the spleen and replenishing blood; the Chinese angelica, prepared rehmannia rhizome, white peony root and ass-hide glue have the effects of nourishing yin, replenishing blood, reinforce vital energy and nourishing essence of kidney; the rice malt has the effects of regulating qi-flowing for harmonizing stomach; and the epimedium herb has the effects of tonifying the kidney and warming yang. The medicament for treating the qi-blood deficiency can be used for effectively improving the illness state of a patient, has a certain treatment effect, and is a medicament for treating the qi-blood deficiency with a good curative effect, quick response and a remarkable effect.
552,377. Artificial teeth. KINNEAR, R. A., and IMPERIAL CHEMICAL INDUSTRIES, Ltd. Oct. 1, 1941, No. 12705. [Class 81 (ii)] A process for the production of dentures containing synthetic resin teeth comprises removing the teeth from a model of a denture, reproducing the model in a synthetic resin or vulcanized rubber dental base, cleaning up the reproduction, inserting the teeth previously removed from the model, or identical teeth, into the appropriate sockets, cementing them in and thereafter removing surplus cement. The teeth may be composed substantially of polymethylmethacrylate resin. Specification 546,360, [Group IV], is referred to.
An exercise monitoring system and method for comparing the present movement of the exercise machine caused by the physical exertion of a user with the user's past movement of the exercise machine. The system includes an exercise monitoring main unit, an exercise monitoring screen, a portable personal memory module, an exercise machine monitoring device, and an exercise monitoring analyzer. The exercise machine monitoring device measures the movement of the exercise machine and provides data representative thereof. The portable personal memory provides data representative of the user's past movement of the exercise machine. The exercise monitoring main unit compares the data and generates a pacing signal on the exercise monitoring screen for the user. The user follows the pacing signal to duplicate his previous performance. The exercise monitoring screen discipline the user's present pace compared to his past pace. The display includes a row of red, yellow and green lights which indicate whether the user is exercising too slowly or too fast. The user can optionally update the portable personal memory with his present performance. The portable personal memory can be transported to provide training on various exercise machines.
SHR2554: 350mg/day, PO, twice a day, every 3 weeks. SHR1701: recommended dose from phase I trial, IV over 30 minutes, every 3 weeks.
Dulaglutide is injected via pen s.c. once a week. The titration scale will be 1x 1.5mg in 0.5 ml in the first week and 2x 1.5 mg in 2x 0.5 ml once weekly for 3 further weeks. Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
Stakeholder-based participatory research will be conducted after CFIR-ERIC mapping activities to focus on partnerships, engagement, co-learning, and developing interventions incorporating interventions on existing practices. Three workshops will be held to reach agreements on the intervention tools, the implementation structure, the data collection procedures and the study audit process among the research team, local policymakers, and implementers. The participants and contents of each workshop are shown in Table 1. At the end of the workshop series, the implementation team from each county prepared a proposed intervention plan describing the steps needed to achieve their goals within a set timeline. The agreed plan of action considered their constraints and how to overcome those barriers.
Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
The study team is seeking volunteers to participate in a research study to help better understand how a behavioral intervention combined with technology may impact weight loss. Participation will span approximately 6 months. Participants will be required to attend up to 5 visits at the University of Chicago. Those visits will include daytime visits to a clinic involving fasted blood draws and completion of surveys. During the study, participants will regularly record their weight using a digital scale, input their daily food intake into a smartphone app, and wear a wrist activity monitor to track their physical activity. Participants will also be paired with a trained coach to guide and assist their progress over their 6 months of participation.
In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
The invention provides a traditional Chinese medicine compound preparation for treating leucoderma.The preparation comprises the following traditional Chinese medicine raw materials as active ingredients in parts by weight: 10-15 parts of Chinese angelica, 15-20 parts of astragalus mongholicus, 5-10 parts of ligusticum wallichii, 5-10 parts of carthamus tinctorius, 10-15 parts of salt-processed fructus psoraleae, 10-15 parts of prepared rhizoma cyperi, 10-15 parts of fried caltrop and 10-15 parts of salvia miltiorrhiza. The traditional Chinese medicine raw materials are processed traditional Chinese medicine powder or traditional Chinese medicine extracts, and the traditional Chinese medicine compound preparation is a powdered preparation, powder, a pill, a pellet, ointment, a granule and the like. The invention provides a preparation method. The traditional Chinese medicine compound preparation has an exact curative effect and no obvious adverse effects. The preparation is convenient to use and carry and has good clinical application prospects. The preparation method is easy and simple to implement and suitable for industrial production, and has a higher application value, and the raw materials are easy to obtain.
The primordial role played by trace elements has been well known by thegeneral public for a long time. The presumption of their existence since thestart of this century and the ensuing research led to the recent scientificdemonstration of their existence, cases of deficiency in the human body andthe need to remedy this. It then emerged that it was necessary to preparesimple and suitable products to make up for said deficiencies. Consequently,the purpose of the present invention is to provide trace element-basedpharmaceutical formulations, in the form of orotic acid salts, which make itpossible to reach the cell directly and restore its normal operation. As anexample, we mention a formulation for the treatment of skin, hair and nails.Indeed, if the visible deficiencies in the human body are successfullyeliminated - for example in the hair, nails and skin, etc. - the otherhidden deficiencies will be improved at the same time. Twelve otherformulations are given as examples among the many possible uses of thepresent invention.
PROBLEM TO BE SOLVED: To ensure easy and fail-proof mounting and to prevent the leakage of semen by incorporating oil of a paraffinic system into a copolymer of polyethylene(PE) and styrene. SOLUTION: An oil of about 98% paraffinic system and about 2% naphthene system is incorporated into the copolymer of PE and styrene. A citrus system may otherwise be used for the oil. Further, carbon and hydrogen are slightly added to the copolymer in both systems. This coating liquid for the penis is applied to the surface from the front end to the root of the penis and is cured before a sexual action. The sexual action is carried out after the curing and after the action, the coating is rolled up and peeled, by which the coating is removed. Since the straight chain of the main agent with this constitution is long, the elongation characteristic is good and the coating liquid is harmless to man and beast. Impact absorptivity and wear resistance are improved and quick drying is made possible.
The invention relates to a free-flowing, powdery composition containing alpha-liponic acid (derivatives). Said composition is characterised in that, along with the liponic acid constituent, it contains between 0.1 and 25 wt. %, in relation to the entire weight of the composition, of a hydrophilic or hydrophobic silicic acid-based liquefying agent having a particle size (x100 value) of less than 800 µm and a tamped density of between 50 and 600 g/L. The liponic acid constituent is not limited to the free acid form, but can at least partially be in the form of its salts. Preferably, spray-dried precipitated silicic acid and/or highly dispersed silicic acids and/or amorphous silica gel are provided as the liquefying agent. The liquefying agent used can not only be characterised by its particle size and its tamped density, but also by its specific surface, which is preferably between 30 and 100 m <2>/g, or by the fact that it causes a pH value between 3 and 11.5 in a 5 % aqueous solution. The invention also relates to a method for producing said composition, whereby the powdery liponic acid constituent is mixed with the solid liquefying agent, and particles larger than 800 µm are then separated from the solid mixture thus obtained. The invention further relates to the use of said composition in solid forms of administration for pharmaceutical, dietetic or cosmetic applications and for producing infusion solutions.
FIELD: medicine. ^ SUBSTANCE: invention relates to veterinary medicine, namely to pharmacology. Composition for treatment of bacterial infections in animals contains florfenicol, benzyl alcohol, water, organic solvent, polyvinylpyrrolidone and solubiliser, with the following component ratio, wt %: florfenicol - 5-35, solubiliser - 5-15, organic solvent - 15-40, benzyl alcohol - 1-2, polyvinylpyrrolidone - 0.1-10, water - the remaining part. As solubiliser solutol HS15 or cremophor, or twin 80 can be used, as organic solvent dimethylacetamide or 2-pyrrolidone or 1-methyl-2-pyrrolidone can be used. Additionally composition can contain flunixin in amount 1-3%. In claimed composition formed is complex compound of florfenicol and polyvinylpyrrolidone, representing supramolecular complex in which between molecules of florfenicol and PVP multiple hydrogen bonds are formed. Composition represents microcolloidal system, stable in definite range of solubiliser and co-solvent concentration. ^ EFFECT: invention ensures reduction of composition toxicity degree, reduction of inflaqmmation process in zone of composition introduction and increase of bioavailability. ^ 4 cl, 2 tbl, 6 ex
The invention discloses a nucleic acid aptamer targeting esophageal squamous carcinoma cells, a screening method and application thereof. Based on the Cell-SELEX technology, KYSE150 cells are used as forward cells, HEEC cells are used as reverse cells, and nucleic acid aptamer EA1 which specifically binds to esophageal squamous carcinoma cells is obtained through repeated rounds of screening. The aptamer is small molecule single-stranded DNA, and the sequence is 5'-ATGGCTTAGTGGCACGATTAGGTCAGGAATCG-3'. Further in vitro and in vivo verification shows that the EA1 aptamer has extremely high affinity and specificity with esophageal squamous carcinoma target cells. The EA1 aptamer can be subjected to fluorescence modification to realize targeted imaging, and can also be used as a target molecule of a nano drug carrier to realize targeted delivery of an antitumor drug. The EA1 aptamer has the advantages of no immunogenicity, small molecular weight, chemical synthesis, good stability, easy modification and the like. The EA1 aptamer provides a high-efficiency and simple molecular tool for clinical accurate diagnosis, personalized treatment, drug targeting delivery and related basic research of occurrence, development and progress of esophageal cancer diseases, and has a wide application prospect.
Methods and a system for managing sessions of physical therapy exercises specific to a patient to maximize outcome are disclosed. Information for each patient includes the sessions to be performed as well as the exercises to be performed within each session. Sensors are attached to specific anatomical landmarks on the patient, depending on the limb to be treated (e.g. hip, shoulder, neck, etc.). The methods and system utilize execution by a data processor to order the exercise data records of the therapy plan data record using input from a monitoring system, store the ordered therapy plan data record, monitor each exercise execution of the patient in real-time according to the ordered therapy plan data record. The method, for instance, can optimize a therapy session for each individual.
AP group was divided into 3 subgroups. The participants in the study group were divided into two subgroups: 35 patients with a PAI score of 3-4 (Group 2: mild-moderate AP), and 55 patients with at least one tooth with a severity of PAI 5 (Group 3: Severe AP).